Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer

NCT01876446 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT01876446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01876446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
August 29, 2013
Completion date
February 24, 2020
Enrollment
38 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent small cell lung carcinoma